TriangleDISEASE & TREATMENT SETTING
INLYTA: advanced Renal cell carcinoma after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
• as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
Broader topic: Renal Cell Cancer
- Source population
- Not part of this definition
- Disease extent
- advanced
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- after failure of one prior systemic therapy
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for INLYTA (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- • as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
Study evidence for this setting
No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice